Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

/PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders, today announced that...

Related Keywords

Boston ,Massachusetts ,United States ,Mahesh Patel ,Tarun Sanyal ,Stravitz Sanyal Institute For Liver Disease ,Prnewswire Lipocine Inc ,Nasdaq ,Metabolic Health ,Virginia Commonwealth University ,Central Nervous System ,American Association ,Liver Diseases ,Liver Meeting ,Stravitz Sanyal Institute ,Liver Disease ,Open Label Extension ,Lipocine Inc ,